Investors navigating today’s market face a difficult task: separating genuinely strong businesses from stocks that simply carry expensive valuations without the fundamentals to back them up.
The gap between quality companies and overpriced ones is widening quickly, making stock selection more critical than ever for portfolio performance this year.
Raytheon (NYSE: RTX), originally focused on refrigeration technology, now provides a broad range of products and services across the aerospace and defense industries.
RTX has demonstrated healthy organic revenue growth, averaging 10.5% over the past two years without relying on acquisitions to drive those gains.
The company’s earnings per share have grown at an annual rate of 16.3% over the last five years, outpacing revenue growth thanks in large part to consistent share repurchases.
RTX’s free cash flow margin expanded by 5.2 percentage points over the last five years, giving management greater flexibility to invest, return capital to shareholders, or pursue dividends.
At a current price of $223.08 per share, RTX trades at a forward price-to-earnings ratio of 30.3x, a premium that appears more justified given its underlying business performance.
On the other side of the ledger, Concrete Pumping (NASDAQ: BBCP) presents a far less compelling picture for investors considering the stock at current levels.
BBCP’s revenue has declined by 4.1% annually over the last two years, suggesting customers have consistently pulled back on purchasing the company’s concrete pumping and waste management services.
Earnings per share at Concrete Pumping have contracted by 33.1% annually over the same two-year period, a deeply troubling trend given how closely stock prices track long-term EPS performance.
The company’s return on capital sits at just 6.6%, reflecting management’s difficulties in identifying and executing on profitable growth opportunities within its core markets.
Despite these challenges, BBCP currently trades at $9.74 per share, representing a forward P/E ratio of 44x, a valuation that appears difficult to justify against such deteriorating fundamentals.
AMN Healthcare Services (NYSE: AMN), which provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms, also faces significant headwinds heading into the back half of 2026.
The number of travelers on assignment through AMN has been declining over the past two years, a trend that could force the company to lower prices in order to stimulate demand and accelerate growth.
AMN’s earnings per share have fallen by 7.6% annually over the past five years, a sustained decline that raises serious questions about the company’s ability to generate consistent shareholder value.
Waning returns on capital at AMN further suggest that the profit engines that once drove the business are losing momentum, making the stock’s forward P/E of 36.2x at $36.46 per share hard to defend.
The broader lesson across these three names is that a high stock price or elevated valuation ratio alone says little about whether a company is worth owning at any given moment.
Strong fundamentals, consistent cash flow growth, and disciplined capital allocation separate genuinely high-quality businesses from those simply trading at a premium without the performance to match.
